Barclays’s Alterity Therapeutics ATHE Stock Holding History

Barclays’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-2,500	Closed	-$300K	–	7594
2014 Q1	$300K	Buy	+2,500	New	+$1.38M	﹤0.01%	4399

Other funds holding ATHE

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's ATHE Position: Q2 2014 in Review

Barclays sold out of Alterity Therapeutics (ATHE) in Q2 2014, closing a stake of 1,934 shares — an estimated $232K sold.

Barclays first reported a position in ATHE in Q4 2013 and held it in 2 quarters. The position peaked at $232K in Q1 2014. 26 funds tracked by Wall St. Rank hold ATHE as of Q2 2014.

Barclays reported no remaining Alterity Therapeutics position as of Q2 2014 after selling out during the quarter.
Barclays sold 1,934 Alterity Therapeutics shares in Q2 2014, an estimated $232K.
Barclays first reported a position in Alterity Therapeutics in Q4 2013 and held it in 2 quarters.
Barclays's Alterity Therapeutics position peaked at $232K in Q1 2014.
26 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2014.

Based on Barclays's 13F filing for Q2 2014, filed 14 Aug 2014.